跳至主要内容
临床试验/ISRCTN96424062
ISRCTN96424062已完成未知

Evaluation of the SenzaTM Spinal Cord Stimulation System for the treatment of chronic back pain in subjects without prior spinal surgery

evro Corp (USA)0 个研究点目标入组 21 人开始时间: 2012年10月26日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
21

研究概览

简要总结

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • 1. Age greater than 18 years, less than 65 years old
  • 2. Low back pain for more than 6 months having failed conservative treatment (e.g., physical therapy, multiple facet joint injections)
  • 3. Low back pain intensity =5 out of 10 cm on the Visual Analog Scale (VAS) at enrollment
  • 4. Low back pain predominates over any radicular pain (VAS back pain 2 points or more greater than VAS leg pain)
  • 5. Degenerative disc disease confirmed by imaging or internal disc disruption as confirmed by discography
  • 6. On stable pain medications, as determined by the Investigator, for at least 28 days prior to enrolling in this study and not change medication dosage without consulting Investigator
  • 7. Legally able to provide informed consent
  • 8. Able to comply with study-related requirements, procedures and visits

排除标准

  • 1. Had previous spinal fusion surgery
  • 2. A current diagnosis of a progressive neurological disease such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, rapidly progressive diabetic peripheral neuropathy, brain or spinal cord tumor, or severe/critical central or foraminal spinal stenosis
  • 3. Mechanical spine instability detected by a spinal surgeon (validation by flexion/extension films of lumbar spine within the past 6 months showing 4 mm or more translational movement or excessive angular movement manifested by >5 degrees segmental angular movement) e.g. any forms of spondylolisthesis
  • 4. A medical condition or pain in other area(s), not intended to be treated with SCS, that could interfere with study procedures, accurate pain reporting, and/or confound evaluation of study endpoints, as determined by the Investigator
  • 5. Diabetic who is poorly controlled through diet and/or medication (determined by the Investigator)
  • 6. Bleeding diathesis such as coagulopathy or thrombocytopenia
  • 7. Immunocompromised and at an increased risk for infection
  • 8. Systemic infection or local infection that would contraindicate SCS placement
  • 9. Metastatic malignant disease or active local malignant disease
  • 10. Pregnant (if female and sexually active, subject must be using a reliable form of birth control, be surgically sterile or be at least 2 years post-menopausal)
  • 11. Active alcohol, marijuana, recreational or prescription drug abuse or dependence or unwilling to stop/reduce excessive inappropriate medication.
  • 12. Evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance of intervention and/or ability to evaluate treatment outcome as determined by the Investigator
  • 13. Life expectancy of less than 1 year
  • 14. Concomitant participation in clinical trial (device or drug)
  • 15. An existing drug pump, SCS system, and/or another active implantable device
  • 16. An interventional procedure and/or surgery within the past 30 days for treatment of pain condition
  • 17. Inability to manage the technical demands of the SCS equipment

研究者

发起方
evro Corp (USA)

相似试验